Clinical Trials

Accrual Status
Limit to SWOG Trials

1040 Results

    View
    Open
    Phase
    Accrual
    0%
    SWOG Clinical Trial Number
    21CTP.HN01

    Phase II Study of Amivantamab carboPlatin and pacliTaxel in recurrent metastatic Head and Neck cancer (CAPT-HN) Study Synopsis
    Status Notes
    Activation - Effective 09/15/2025

    SWOG Clinical Trials Partinerships
    https://www.swogctp.org/trials/21ctphn01/
    Research Committee(s)
    SWOG CTP
    Head and Neck Cancer
    Activated
    09-15-2025
    ClinicalTrials.gov Registry Number
    07062354
    Open
    Phase
    Accrual
    0%
    SWOG Clinical Trial Number
    S2427

    Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
    Status Notes
    Active as of 9/4/2025.
    Research Committee(s)
    Genitourinary Cancer
    Activated
    09-04-2025
    ClinicalTrials.gov Registry Number
    07061964
    Open
    Phase
    Accrual
    1%
    SWOG Clinical Trial Number
    S2417CD

    A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance
    Status Notes
    This study is open to accrual, effective 8/4/2025 at 12:00 p.m. PT.
    Research Committee(s)
    Cancer Care Delivery
    Gastrointestinal Cancer
    Activated
    08-04-2025
    ClinicalTrials.gov Registry Number
    NCT 07018869
    Open
    Phase
    Accrual
    9%
    SWOG Clinical Trial Number
    S1800E

    A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
    Status Notes
    Effective April 28, 2025 at 12:00 p.m. Pacific Time, sub-study S1800E will be open to accrual. This is a potential FDA Registration Trial. Additional site requirements include:
    • maintenance of a Trial Master File (See the Trial Master File guidance document, accessible from the Protocol Workbench at https://www.swog.org/clinical-trials/protocol-workbench)
    • completion of a protocol specific Delegation of Task Log (DTL) (see Section 13.2)
    • additional monitoring (see Section 18.3)
    Research Committee(s)
    LungMAP
    Activated
    04-28-2025
    ClinicalTrials.gov Registry Number
    NCT06616584
    Open
    Phase
    Accrual
    8%
    SWOG Clinical Trial Number
    MM1OA-S03

    A Randomized Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML: A myeloMATCH Substudy
    Research Committee(s)
    myeloMATCH
    Leukemia
    Activated
    04-01-2025
    ClinicalTrials.gov Registry Number
    NCT06672146
    Open
    Phase
    Accrual
    2%
    SWOG Clinical Trial Number
    S2414

    INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
    Status Notes
    Initial Activation-Effective March 14, 2025, at 12:00 p.m. Pacific Time
    Research Committee(s)
    Lung Cancer
    Symptom Control and Quality of Life
    Activated
    03-14-2025
    ClinicalTrials.gov Registry Number
    06498635